Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 1.00 |
| ▸ | EPHA2 | P29317 | 4/20 | 1.00 |
| ▸ | CASP7 | P55210 | 3/20 | 1.00 |
| ▸ | VDR | P11473 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | MDM4 | O15151 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HSPD1 | P10809 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | PTPN2 | P17706 | 1/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithocholic Acid SCHEMBL22756077 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2CASP7VDRHIF1A | |
| Lithocholic Acid SCHEMBL22894393 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2CASP7VDRHIF1A | |
| Lithocholic Acid SCHEMBL22871939 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2CASP7VDRHIF1A | |
| Lithocholic Acid SCHEMBL22079173 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2CASP7VDRHIF1A | |
| Lithocholic Acid SCHEMBL24001494 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2CASP7VDRHIF1A | |
| Lithocholic Acid SCHEMBL22894425 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2CASP7VDRHIF1A | |
| Lithocholic Acid SCHEMBL23923735 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2CASP7VDRHIF1A | |
| Lithocholic Acid SCHEMBL24001453 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2CASP7VDRHIF1A | |
| Lithocholic Acid SCHEMBL24567422 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2CASP7VDRHIF1A | |
| Lithocholic Acid SCHEMBL22415871 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2CASP7VDRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3869192-B1 | METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE | HUMAN METABOLOMICS INST INC (CN) | 2026-05-13 | — | — | EP | claimed |
| US-20260085364-A1 | USE OF BIOMARKERS IN TREATMENT WITH BIFIDOBACTERIA | INT N&H DENMARK APS (DK) | 2026-03-26 | — | — | US | claimed |
| EP-4702980-A1 | ISOLITHOCHOLIC ACID FOR USE IN THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES OF THE RESPIRATORY SYSTEM | Instytut Biologii Doswiadczalnej PAN. im. M. Nenckiego (PL) | 2026-03-04 | — | — | EP | claimed |
| US-20250258146-A1 | QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP | HUMAN METABOLOMICS INSTITUTE INC. (CN) | 2025-08-14 | — | — | US | claimed |
| EP-4591065-A1 | USE OF BIOMARKERS IN TREATMENT WITH BIFIDOBACTERIA | International N&H Denmark ApS (DK) | 2025-07-30 | — | — | EP | claimed |
| WO-2025128875-A1 | COMPOSITIONS, KITS, AND METHODS FOR ASSESSING MICROBIOME HEALTH | THE UNIVERSITY OF CHICAGO (US) | 2025-06-19 | — | — | WO | claimed |
| CN-119923565-A | Use of biomarkers in treatment with bifidobacteria | 国际N&H丹麦有限公司 | 2025-05-02 | — | — | CN | claimed |
| US-20240342201-A1 | ASYMMETRIC GPR84 ANTAGONIST AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2024-10-17 | — | — | US | claimed |
| CN-117630240-B | Extraction and quantitative detection method of 87 bile acids in feces and intestinal contents | 浙江大学 | 2024-09-03 | — | — | CN | claimed |
| CN-118566493-A | Preparation method of blood reference product applied to next generation metabonomics | 上海阿趣生物科技有限公司 | 2024-08-30 | — | — | CN | claimed |
| WO-2022132678-A1 | BIOLOGICAL DELIVERY SYSTEMS | DNALITE THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | claimed |
| EP-3982932-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | Dnalite Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | claimed |
| US-20220026398-A1 | QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP | HUMAN METABOLOMICS INSTITUTE INC. (CN) | 2022-01-27 | — | — | US | claimed |
| EP-3875596-A1 | METHOD FOR HYDROXYLATION OF STEROIDS | Pharmazell GmbH (DE) | 2021-09-08 | — | — | EP | claimed |
| EP-3875597-A1 | METHOD FOR HYDROXYLATION OF STEROIDS | Annikki GmbH (AT) | 2021-09-08 | — | — | EP | claimed |
| US-20210148893-A1 | METHOD FOR DETERMINING IN VITRO BIOEQUIVALENCE OF A SUCRALFATE SUSPENSION SAMPLE TO A SUCRALFATE SUSPENSION REFERENCE LISTED DRUG (RLD) | CLAYTON PHARMACEUTICALS LLC (US) | 2021-05-20 | — | — | US | claimed |
| EP-3423829-B1 | METHOD FOR DETERMINING IN VITRO BIOEQUIVALENCE OF A SUCRALFATE SUSPENSION SAMPLE TO A SUCRALFATE SUSPENSION REFERENCE LISTED DRUG (RLD) | CLAYTON PHARMACEUTICALS LLC (US) | 2020-10-28 | — | — | EP | claimed |
| EP-3423829-A1 | METHOD FOR DETERMININGIN VITRO | Clayton Pharmaceuticals LLC (US) | 2019-01-09 | — | — | EP | claimed |
| WO-2018204894-A1 | METHOD FOR DETERMINING IN VITRO BIOEQUIVALENCE OF A SUCRALFATE SUSPENSION SAMPLE TO A SUCRALFATE SUSPENSION REFERENCE LISTED DRUG (RLD) | CLAYTON PHARMACEUTICALS LLC (US) | 2018-11-08 | — | — | WO | claimed |
| US-9989519-B1 | Method for determining in vitro bioequivalence of a sucralfate suspension sample to a sucralfate suspension reference listed drug (RLD) | Clayton Pharmaceuticals, LLC (US) | 2018-06-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240342201-A1 | ASYMMETRIC GPR84 ANTAGONIST AND USE THEREOF | GPR84, GPR65, GPR88 | GPBAR1 24/4885EPHA2 1448/4885CASP7 2556/4885 |
| US-20260085364-A1 | USE OF BIOMARKERS IN TREATMENT WITH BIFIDOBACTERIA | FABP2, ALPI, CES1 | GPBAR1 58/4885EPHA2 760/4885CASP7 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.